Outlook Therapeutics
Joel Prieve is a Senior Vice President at Outlook Therapeutics, Inc. where Joel oversees licensing, partnerships, and mergers & acquisitions. Joel has a strong background in business development within the pharmaceutical industry, having previously worked at AmerisourceBergen, Xcenda, and AMAG Pharmaceuticals. Joel's expertise lies in pricing strategies, C-Suite access, key account management, product commercialization, and strategic business planning. Joel holds an MBA in Management and Entrepreneurship from Pepperdine Graziadio Business School.
This person is not in any offices
Outlook Therapeutics
Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO.